Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Publication
, Journal Article
Willett, CG; Boucher, Y; di Tomaso, E; Duda, DG; Munn, LL; Tong, RT; Chung, DC; Sahani, DV; Kalva, SP; Kozin, SV; Mino, M; Cohen, KS; Zhu, AX ...
Published in: Nat Med
February 2004
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Med
DOI
ISSN
1078-8956
Publication Date
February 2004
Volume
10
Issue
2
Start / End Page
145 / 147
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Rectal Neoplasms
- Immunology
- Humans
- Bevacizumab
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Angiogenesis Inhibitors
- Adenocarcinoma
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., … Jain, R. K. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10(2), 145–147. https://doi.org/10.1038/nm988
Willett, Christopher G., Yves Boucher, Emmanuelle di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, et al. “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.” Nat Med 10, no. 2 (February 2004): 145–47. https://doi.org/10.1038/nm988.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb;10(2):145–7.
Willett, Christopher G., et al. “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.” Nat Med, vol. 10, no. 2, Feb. 2004, pp. 145–47. Pubmed, doi:10.1038/nm988.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb;10(2):145–147.
Published In
Nat Med
DOI
ISSN
1078-8956
Publication Date
February 2004
Volume
10
Issue
2
Start / End Page
145 / 147
Location
United States
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Rectal Neoplasms
- Immunology
- Humans
- Bevacizumab
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Angiogenesis Inhibitors
- Adenocarcinoma
- 42 Health sciences